Literature DB >> 6279061

Ocular effects of topical administration of delta 9-tetrahydrocannabinol in man.

K Green, M Roth.   

Abstract

delta 9-Tetrahydrocannabinol (THC) or vehicle alone was applied topically to one eye of normal paid volunteers. Ocular and systemic toxic effects and intraocular responses were measured in different series. Toxicity was limited to minor conjunctival injection that was of short (less than 60 minutes) duration and occurred with both drug and vehicle alone. Subjective responses indicated a sensation of minor burning and/or tearing. No fall in intraocular pressure was found. A small (1 mm) but significant mydriasis occurred in both the treated eye and untreated eye and was not drug related. Single-drop administration of delta 9-THC did not, therefore, cause any significant ocular irritation or reduce IOP.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6279061     DOI: 10.1001/archopht.1982.01030030267006

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  14 in total

1.  Enhanced solubility, stability, and transcorneal permeability of δ-8-tetrahydrocannabinol in the presence of cyclodextrins.

Authors:  Ketan Hippalgaonkar; Waseem Gul; Mahmoud A ElSohly; Michael A Repka; Soumyajit Majumdar
Journal:  AAPS PharmSciTech       Date:  2011-06-03       Impact factor: 3.246

2.  Effect of ion pairing on in vitro transcorneal permeability of a Δ(9) -tetrahydrocannabinol prodrug: potential in glaucoma therapy.

Authors:  Tushar Hingorani; Waseem Gul; Mahmoud Elsohly; Michael A Repka; Soumyajit Majumdar
Journal:  J Pharm Sci       Date:  2011-10-11       Impact factor: 3.534

3.  Ocular Disposition of ∆8-Tetrahydrocannabinol from Various Topical Ophthalmic Formulations.

Authors:  Nagendra S Punyamurthula; Goutham R Adelli; Waseem Gul; Michael A Repka; Mahmoud A ElSohly; Soumyajit Majumdar
Journal:  AAPS PharmSciTech       Date:  2016-11-30       Impact factor: 3.246

4.  Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of action.

Authors:  Matt H Oltmanns; Sandeep S Samudre; Ivan G Castillo; Alireza Hosseini; Aron H Lichtman; Robert C Allen; Frank A Lattanzio; Patricia B Williams
Journal:  J Ocul Pharmacol Ther       Date:  2008-02       Impact factor: 2.671

5.  A3 adenosine and CB1 receptors activate a PKC-sensitive Cl- current in human nonpigmented ciliary epithelial cells via a G beta gamma-coupled MAPK signaling pathway.

Authors:  Chanjuan Shi; Anna Szczesniak; Lucy Mao; Christine Jollimore; Miguel Coca-Prados; Orlando Hung; Melanie E M Kelly
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

Review 6.  Cannabinoids and glaucoma.

Authors:  I Tomida; R G Pertwee; A Azuara-Blanco
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

7.  Ocular disposition of the hemiglutarate ester prodrug of ∆⁹-Tetrahydrocannabinol from various ophthalmic formulations.

Authors:  Tushar Hingorani; Goutham R Adelli; Nagendra Punyamurthula; Waseem Gul; Mahmoud A Elsohly; Michael A Repka; Soumyajit Majumdar
Journal:  Pharm Res       Date:  2013-06-05       Impact factor: 4.200

8.  Heat shock protein 90 is an essential molecular chaperone for CB2 cannabinoid receptor-mediated signaling in trabecular meshwork cells.

Authors:  Fang He; Akhilesh Kumar; Zhao-Hui Song
Journal:  Mol Vis       Date:  2012-11-29       Impact factor: 2.367

Review 9.  Marijuana for Glaucoma: A Recipe for Disaster or Treatment?

Authors:  Xiaoshen Sun; Chaoying S Xu; Nisha Chadha; Allshine Chen; Ji Liu
Journal:  Yale J Biol Med       Date:  2015-09-03

Review 10.  Turning Down the Thermostat: Modulating the Endocannabinoid System in Ocular Inflammation and Pain.

Authors:  James T Toguri; Meggie Caldwell; Melanie E M Kelly
Journal:  Front Pharmacol       Date:  2016-09-15       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.